{
    "clinical_study": {
        "@rank": "112605", 
        "arm_group": [
            {
                "arm_group_label": "HBV-3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one dose HBV"
            }, 
            {
                "arm_group_label": "HBV-6", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one dose HBV"
            }, 
            {
                "arm_group_label": "varicella-3", 
                "arm_group_type": "Experimental", 
                "description": "2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time"
            }, 
            {
                "arm_group_label": "varicella-6", 
                "arm_group_type": "Experimental", 
                "description": "2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time"
            }
        ], 
        "brief_summary": {
            "textblock": "Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune\n      procedure we could supply scientific and practical evidence for this two doses immune\n      procedure promotion and management."
        }, 
        "brief_title": "The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Varicella", 
        "condition_browse": {
            "mesh_term": [
                "Chickenpox", 
                "Herpes Zoster"
            ]
        }, 
        "detailed_description": {
            "textblock": "Healthy participants aged 1 to 12 years old who had never received Varicella Vaccine are\n      divided into three age groups, 1 to 3 years old group, 4 to 6 years old group and 7-12 years\n      old group. In each age group, participants are randomly divided into experiment group and\n      control groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Participants from Shanxi province are between 1-12 years old are in good         healthy\n        determined through medical inquiry, physical examination, clinical  judgment of the\n        investor.\n\n        Exclusion Criteria:\n\n          1. Having a fever (axillary temperature\uff1e37.0\u2103) before enrollment;\n\n          2. Having a disease history of seizures, brain disease and the vaccination history of\n             allergies and convulsions;\n\n          3. Antibiotics allergy;\n\n          4. Having a problem of intramuscular injection because thrombocytopenia or other blood\n             coagulation disorder;\n\n          5. Having immunodeficiency or under immunosuppression therapy, radiation therapy;\n\n          6. Having respiratory diseases, acute infection, chronic disease and HIV infection;\n\n          7. Having systemic skin rash, skin tinea, herpes;\n\n          8. Chronic liver and kidney disease;\n\n          9. Heart disease, and severe hypertension;\n\n         10. Have received whole blood, plasma or immunoglobulin therapy 3 months before\n             enrollment;\n\n         11. Have received other live attenuated vaccine vaccination in 30 days before enrollment;\n\n         12. Had been infected with Varicella virus and displayed symptom;\n\n         13. Have received one or two dose of Varicella vaccine before enrollment;\n\n         14. Congenital malformations, growth disorders such as Down's syndrome, diabetes, sickle\n             cell anemia and nervous disorders\n\n         15. Guillain-barre syndrome\n\n         16. Thyroid resection history or thyroid disease treatment in the past 12 months;\n\n         17. Asthma\n\n         18. Have participated in other clinical research;\n\n         19. Have serious adverse reactions after vaccination, such as allergies, hives, breathing\n             difficulties, angioneurotic edema."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "1800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866566", 
            "org_study_id": "BJCDPC-9"
        }, 
        "intervention": [
            {
                "arm_group_label": "HBV-3", 
                "description": "Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month", 
                "intervention_name": "HBV-3", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HBV-6", 
                "description": "Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month", 
                "intervention_name": "HBV-6", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "varicella-3", 
                "description": "Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month", 
                "intervention_name": "varicella-3", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "varicella-6", 
                "description": "Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month", 
                "intervention_name": "varicella-6", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "contact": {
                "last_name": "Li"
            }, 
            "facility": {
                "address": {
                    "city": "Yuncheng", 
                    "country": "China", 
                    "state": "Shanxi"
                }, 
                "name": "Shanxi Centers for Disease Control and Prevention"
            }, 
            "investigator": {
                "last_name": "Guohua Li", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination", 
        "other_outcome": {
            "measure": "Number of participants who catch chickenpox", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "overall_contact": {
            "email": "cycdc2011@163.com", 
            "last_name": "Nianmin Shi", 
            "phone": "86-010-67773550"
        }, 
        "overall_contact_backup": {
            "last_name": "Li Li"
        }, 
        "overall_official": {
            "affiliation": "Beijing Chaoyang District Centers for Disease Control and Prevention", 
            "last_name": "Nianmin Shi", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Serums are collected from all participants before and 42 days after the first vaccination, and also 42 days after the second vaccination. The antibody titer to Varicella was detected through FAMA test.", 
            "measure": "Antibody titer after 2 doses lived attenuated varicella vaccination", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866566"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The safety is evaluated by systemic and local reaction after each vaccination.", 
            "measure": "Number of participants who have adverse reaction", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Beijing Center for Disease Control and Prevention", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}